Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

A third program from the company has entered the clinical development phase using the FORCE platform. The objective is to achieve significant functional improvement in a rare neuromuscular disease. This initiative underscores the company's commitment to addressing rare diseases through innovative solutions.